US: FDA relied on Real-World Evidence for Hepcludex (bulevirtide) as hepatitis D treatment’s confirmatory study under accelerated approval

Immagine News

The US Food and Drug Administration allowed Gilead to rely on real-world evidence to confirm the clinical benefit of its hepatitis D drug Hepcludex (bulevirtide-gmod) through an ongoing, non-interventional, retrospective, observational study.

The design is unusual for a confirmatory study of an accelerated approval product. The agency’s preference usually is for randomized controlled trials or even single-arm, prospective interventional trials using a historical comparison.

The FDA’s premarket review of bulevirtide also partially relied on extensive real-world experience outside the US, which gave the agency confidence in the drug’s safety and efficacy profile.

The FDA granted accelerated approval to bulevirtide 8.5 mg on May 22 based on a clinically meaningful and statistically significant improvement in combined virologic and biochemical response compared to delayed treatment in the Phase III MYR301 trial.

To support conversion from accelerated to regular approval, Gilead is conducting Study GS-EU-589-6575, an observational trial using RWE to demonstrate bulevirtide’s clinical benefit, the FDA’s multi-discipline review states.

The study will compare the incidence of liver-related events, including development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation and liver-related death, in adults with chronic HDV infection treated with bulevirtide (2 mg or 10 mg) versus a historical control group of patients who received standard of care and were not treated with bulevirtide.

Gilead studied a 10 mg dose in the Phase II and III trials that supported accelerated approval, but the FDA approved an 8.5 mg dose based on the amount of drug actually delivered, according to a dose recovery study.

Cohort entry for the bulevirtide groups is at drug initiation as early as 2019, while cohort entry in the control group is at a random visit when eligibility criteria were met, as early as 2013.

The number of patients in each group are redacted from the FDA’s review memo. The groups will be matched using propensity score methods and followed for up to five years.

“FDA agreed in November 2023 that the RWE approach had the potential to confirm clinical benefit, but raised important concerns about data quality and completeness, requesting comprehensive feasibility assessments from all participating sites (not just a subset) to ensure that data are fit-for-purpose,” the multi-discipline review states. 

Following several redacted lines, the memo states that “ultimately, the FDA and applicant reached agreement on the confirmatory study design” and that “study GS-EU-589-6575 was to initiate data collection in Q1 2025 across approximately 60-85 sites in 11-12 countries.”

The date of the expected first interim data quality assessment is redacted from the review memo. The study is targeted for completion in February 2033, with final report submission by June 2034, the approval letter states.

FDA officials continue to push for more use of RWE in drug development, as well as regulatory decision-making. The agency recently asked for ideas on avoiding problems with data agreements that can hinder real-world data use in application reviews.

 

Source

Grazie per il tuo feedback!